Published online Oct 6, 2020. doi: 10.12998/wjcc.v8.i19.4311
Peer-review started: April 4, 2020
First decision: June 18, 2020
Revised: July 1, 2020
Accepted: August 29, 2020
Article in press: August 29, 2020
Published online: October 6, 2020
Transanal minimally invasive surgery (TAMIS) is a good choice for resection of benign lesions and carcinoids in the rectum. Endoscopic mucosal resection (EMR) is also widely used in the treatment of benign rectal tumors such as rectal polyps and rectal adenomas. However, no studies have compared the outcome of TAMIS and EMR.
We hope that this study will help surgeons in the choice of treatment for benign rectal lesions and rectal carcinoids.
We compared the short-term outcomes after TAMIS and EMR for rectal carcinoid and benign tumors (including rectal polyps and adenomas).
The short-term outcomes after TAMIS and EMR for rectal carcinoids and benign tumors (including rectal polyps and adenomas) was compared.
TAMIS was associated with a higher urinary retention rate (13.6%, 6/44 vs 1.9%, 1/53 P = 0.026) and lower hemorrhage rate (0%, 0/44 vs 18.9%, 10/53 P = 0.002). A significantly higher reoperation rate was observed in the EMR group (9.4%, 5/53 vs 0%, 0/44 P = 0.036).
Compared with EMR, TAMIS can remove rectal tumors more completely with effective hemostasis and lower postoperative hemorrhage and reoperation rates. TAMIS is a better choice for the treatment of rectal carcinoids and benign rectal tumors with a large diameter.
TAMIS surgery requires more surgical instruments, a larger surgical field, deeper and more thorough tumor resection, more effective hemostasis and results in lower hemorrhage and reoperation rates. It is a better choice for the treatment of rectal carcinoids.